<p align="center">
  <img src="https://github.com/user-attachments/assets/1ac818d1-0cbe-49d3-ad4f-764d3add6c5b" width="300">
</p>
<br>
<br>
# SurvSig
## SurvSig is a web-based tool for complex gene signature analysis in neuroendocrine lung tumors and TCGA.

ðŸ”— Access the application here: **[www.survsig.hcemm.eu](https://survsig.hcemm.eu/)** <br>
ðŸ’¡ **No installation required** â€“ just open the website and start analyzing!

About SurvSig
SurvSig is an interactive web application designed for clinicians and researchers working with neuroendocrine lung tumors (SCLC, LCNEC, carcinoid tumors). It enables users to analyze complex gene signatures and explore their relationship with patient outcomes.

Key Features\
âœ” Easy-to-use web interface â€“ No coding or bioinformatics expertise required.\
âœ” Supports multiple datasets, including:

Small Cell Lung Cancer (SCLC): George-SCLC, Liu-SCLC, Lissa-SCLC, Jiang-SCLC<br>
Large-Cell Neuroendocrine Carcinoma (LCNEC): George-LCNEC<br>
Carcinoid Tumors: Alcala-Carcinoid, Fernandez-Carcinoid<br>
Mixed Cohort Data: Rousseaux Lung Tumors, TCGA <br>âœ” Gene signature-based analysis â€“ Upload your own gene list or use predefined signatures.<br>
âœ” Advanced visualization tools, including heatmaps, UMAP clustering, and survival curves.<br><br>
![KÃ©pernyÅ‘kÃ©p 2025-03-20 14-00-19](https://github.com/user-attachments/assets/f684b2aa-9bcf-4ae7-a13c-24766a18db9f)<br><br>
## **How to Use**
Visit **[www.survsig.hcemm.eu](https://survsig.hcemm.eu/)** <br>
Select a dataset and an analysis type.<br>
Upload your gene list or choose a predefined signature.<br>
View survival analysis results, heatmaps, and enrichment scores.<br>
## **Why Use SurvSig?**
ðŸ”¹ Designed specifically for neuroendocrine lung tumors.<br>
ðŸ”¹ Works with real-world patient data from multiple studies.<br>
ðŸ”¹ Helps identify clinically relevant molecular subtypes using machine learning.<br>
ðŸ”¹ No need for coding or complex bioinformatics pipelines.<br>

**Citation**<br>
*If you use SurvSig in your research, please cite:*<br>
*Nemes et al., 2025 (manuscript in preparation)*
